Krystal Biotech Balance Sheet
NASDAQ: KRYSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Krystal Biotech financial position
At the end of fiscal 2025, Krystal Biotech reported total assets of $1.33 billion, up 26.3% from a year earlier against total liabilities of $114.2 million. Shareholders' equity stood at $1.22 billion, or 91.4% of assets. The company held $496.3 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 9.95, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Krystal Biotech balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20212022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 496.30M | 344.87M | 358.33M | 161.90M | 341.25M | 268.27M | 187.51M | 103.67M | 49.59M | 1.92M |
| Short-Term Investments | 331.49M | 252.65M | 173.85M | 217.27M | 96.85M | 2.99M | 6.17M | 8.09M | — | — |
| Receivables | 127.42M | 104.75M | 42.04M | 0 | — | — | — | — | — | — |
| Inventory | 40.48M | 26.51M | 6.99M | 0 | — | — | — | — | — | — |
| Total Current Assets | 1.02B | 742.04M | 587.91M | 383.78M | 442.27M | 275.06M | 195.88M | 112.65M | 49.91M | 2.17M |
| Property, Plant & Equipment | 150.78M | 155.17M | 161.20M | 161.68M | 112.36M | 30.88M | 8.47M | 3.01M | 200.00K | 13.00K |
| Long-Term Investments | 128.07M | 152.11M | 61.95M | 4.62M | 64.37M | 0 | 497.00K | — | — | — |
| Total Assets | 1.33B | 1.06B | 818.36M | 558.45M | 626.29M | 310.84M | 209.02M | 116.12M | 50.11M | 2.18M |
| Accounts Payable | 3.24M | 4.99M | 4.13M | 3.98M | 8.40M | 2.10M | 1.02M | 888.00K | 193.00K | 42.00K |
| Total Current Liabilities | 102.94M | 102.00M | 33.09M | 28.85M | 25.74M | 15.45M | 3.33M | 2.60M | 640.00K | 43.00K |
| Total Liabilities | 114.23M | 109.46M | 39.71M | 36.22M | 32.72M | 18.76M | 6.11M | 2.89M | 640.00K | 1.89M |
| Shareholders' Equity | 1.22B | 946.38M | 778.64M | 522.23M | 593.58M | 292.08M | 202.91M | 113.23M | 49.47M | 289.00K |
| Retained Earnings | 24.16M | -180.67M | -269.83M | -280.76M | -140.78M | -71.21M | -39.05M | -19.96M | -9.07M | -1.15M |
| Net Cash (Debt) | 827.79M | 597.52M | 532.18M | 379.17M | 438.10M | 271.26M | 193.69M | 111.76M | 49.59M | 1.92M |
| Shares Outstanding | 29.19M | 28.79M | 28.24M | 25.76M | 25.21M | 19.71M | 17.35M | 14.43M | 10.31M | 0 |
This table shows 10 annual periods of Krystal Biotech's balance sheet, from FY 2025 back to FY 2016, across 15 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow KRYS's reporting calendar. What is a balance sheet?